A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT06669247 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

186

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

DRUG: Linvoseltamab
DRUG: REGN7945+Linvoseltamab

Sponsor

Regeneron Pharmaceuticals